Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for eFFECTOR Therapeutics, Inc. (EFTR : NSDQ)

• Company Description    eFFECTOR Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR Therapeutics Inc., formerly known as Locust Walk Acquisition Corp., is based in SAN DIEGO. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $1.05 Daily Weekly Monthly 20 Day Moving Average: 3,327,000 shares Shares Outstanding: 42.40 (millions) Market Capitalization: $44.52 (millions) Beta: 0.36 52 Week High: $2.07 52 Week Low: $0.34 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 110.04% 102.09% 12 Week 116.50% 100.97% Year To Date 145.56% 123.36%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 142 North Cedros Avenue Suite B - Solana Beach,CA 92075 USA ph: 858-925-8215 fax: - None http://effector.com

• General Corporate Information    Officers Stephen Worland - President and Chief Executive Officer Brian M. Gallagher - Chairman Michael Byrnes - Chief Financial Officer Elizabeth P. Bhatt - Director Chris Ehrlich - Director Peer Information eFFECTOR Therapeutics, Inc. (CORR.) eFFECTOR Therapeutics, Inc. (RSPI) eFFECTOR Therapeutics, Inc. (CGXP) eFFECTOR Therapeutics, Inc. (BGEN) eFFECTOR Therapeutics, Inc. (GTBP) eFFECTOR Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28202V108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/08/23 Share - Related Items Shares Outstanding: 42.40 Most Recent Split Date: (:1) Beta: 0.36 Market Capitalization: $44.52 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.69 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -442.86% vs. Previous Quarter: -9.09% Sales Growth vs. Year Ago Period: 116.72% vs. Previous Quarter: -22.26% ROE 03/31/23 - -472.46 12/31/22 - -150.65 09/30/22 - 30.36 ROA 03/31/23 - -109.05 12/31/22 - -57.26 09/30/22 - 12.18 Current Ratio 03/31/23 - 0.78 12/31/22 - 1.12 09/30/22 - 1.42 Quick Ratio 03/31/23 - 0.78 12/31/22 - 1.12 09/30/22 - 1.42 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - -1,006.42 12/31/22 - -637.91 09/30/22 - 176.98 Book Value 03/31/23 - -0.11 12/31/22 - 0.09 09/30/22 - 0.28 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - - 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - - 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©